We are live on ! Find out more
CPXX

CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX

Delisted

CPXX was delisted on the 11th of July, 2016.

20 hedge funds and large institutions have $5.23M invested in CELATOR PHARMACEUTICALS INC. COMMON STOCK in 2015 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

25% more funds holding

Funds holding: 1620 (+4)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

20% less capital invested

Capital invested by funds: $6.52M → $5.23M (-$1.29M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
20
Holders Change
+4
Holders Change %
+25%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
3
Reduced
5
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Caxton Corporation
New Jersey
$3.73M
Vanguard Group
2
Vanguard Group
Pennsylvania
$852K +$337K +151,643 +42%
California Public Employees Retirement System
3
California Public Employees Retirement System
California
$146K
Geode Capital Management
4
Geode Capital Management
Massachusetts
$111K +$149K +67,015 New
BFA
5
BlackRock Fund Advisors
California
$106K -$3.75K -1,692 -3%
Goldman Sachs
6
Goldman Sachs
New York
$58K +$77.2K +34,795 New
BIT
7
BlackRock Institutional Trust
California
$51K +$68K +30,659 New
TC
8
TFS Capital
Pennsylvania
$37K +$4.58K +2,064 +10%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$36K +$48.7K +21,923 New
Northern Trust
10
Northern Trust
Illinois
$35K +$46K +20,724 New
VKH
11
Virtu KCG Holdings
New York
$27K -$48.3K -21,747 -57%
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$21K +$28.1K +12,650 New
BIM
13
BlackRock Investment Management
Delaware
$7K
Bank of America
14
Bank of America
North Carolina
$5K -$30.9K -13,900 -81%
Wells Fargo
15
Wells Fargo
California
$4K +$4.88K +2,200 New
Creative Planning
16
Creative Planning
Kansas
$4K +$5.77K +2,600 New
UBS Group
17
UBS Group
Switzerland
$1K -$4.74K -2,134 -81%
Morgan Stanley
18
Morgan Stanley
New York
$1K +$883 +398 +686%
NCCM
19
Nine Chapters Capital Management
New Jersey
-$106K -47,400 Closed
RCM
20
Rotella Capital Management
Washington
-$31K -13,995 Closed
Walleye Trading
21
Walleye Trading
New York
-$6K -2,600 Closed
MA
22
MUFG Americas
New York
-$4K -1,910 Closed
TRCT
23
Tower Research Capital (TRC)
New York
-$2.58K -1,164 -98%
CPA
24
Cowen Prime Advisors
New York
-$2K -1,000 Closed
Citigroup
25
Citigroup
New York
+$300 +135 New

CPXX Hedge Fund Activity: Q3 2015 in Review

20 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) for Q3 2015, worth a combined $5.23M — down 20% from $6.52M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CPXX positions and 5 closed out — a net gain of 4 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $337K. The largest seller was Nine Chapters Capital Management, exiting entirely with an estimated $106K sold.

  • 20 institutional investors held CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) as of Q3 2015, up from 16 in Q2 2015.
  • Funds reported $5.23M of CELATOR PHARMACEUTICALS INC. COMMON STOCK stock for Q3 2015, down 20% quarter-over-quarter.
  • 9 funds opened new CELATOR PHARMACEUTICALS INC. COMMON STOCK positions in Q3 2015 and 5 closed out, a net change of +4 holders.
  • The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK buyer in Q3 2015 was Vanguard Group, an estimated $337K added.
  • The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK seller in Q3 2015 was Nine Chapters Capital Management, an estimated $106K sold.

Based on aggregated 13F filings for Q3 2015.